Immunetune Announces Presentations at Industry Conferences during April and May 2022

Apr 20, 2022

Immunetune Announces Presentations at Industry Conferences during April and May 2022


LEIDEN, the Netherlands, April 20, 2022 —
Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the upcoming presentations by members of its management team at several industry and scientific conferences during April and May 2022.


“I am glad to announce that we have been selected to present at the Neoantigen Summit and the Cancer Immunotherapy meeting,”
said Sijme Zeilemaker, CEO of Immunetune. “As our lead program NeoVAC has recently completed GLP toxicity studies, we are looking forward to present our preclinical package and connect with other leaders in this exciting industry of immunotherapies for the treatment of cancer.”


Upcoming conferences:

Innovation for Health, April 21, Amsterdam, the Netherlands

  • CEO Sijme Zeilemaker will be participating.

Neoantigen Summit Europe, April 26 – 28, Amsterdam, the Netherlands

  • CEO Sijme Zeilemaker will take part in the Industry Leader’s Fireside Chat on April 27th, 10:40 – 11:00 AM, on the great challenges and opportunities in cancer vaccine development.
  • CSO Jeroen van Bergen will be presenting on April 27th, 12:00 – 12:30 PM, on ‘Optimizing Vaccine Manufacturing for Targeting Neoantigens’ in the Clinical Translation & Manufacturing track.

Cancer Immunotherapy (CIMT) Annual Meeting, May 10-12, Mainz, Germany

  • CSO Jeroen van Bergen will be giving a poster presentation on May 10th between 3:30 – 6:00 PM.
  • CSO Jeroen van Bergen will be giving an oral presentation in the short-talk session presenting on on May 12th between 9:00 – 10:30 AM.
  • The selected abstract for both sessions is titled “Personalized synthetic polyepitope DNA cancer vaccines including a novel pyroptotic adjuvant synergize with checkpoint inhibitor therapy to generate effective anti-tumor T cell immunity”. Abstracts will be available online prior to the start of the conference.

Knowledge for Growth, May 19, Ghent, Belgium

  • CEO Sijme Zeilemaker will be participating.

 

About Immunetune

Immunetune is a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases. Its proprietary set of technologies allow the rapid, cell-free production of personalized cancer vaccines encoding multiple (neo-)antigens in synthetic, linear DNA with improved immunogenicity through its unique PyroVant™ adjuvant. Its lead cancer vaccine has achieved preclinical Proof of Concept in animal studies and has completed GLP toxicity studies, with the aim to initiate clinical studies in 2022. Immunetune’s pipeline further consists of infectious disease vaccines, including a pan-corona DNA vaccine, targeting antigens conserved across multiple strains of coronaviruses for global pandemic readiness, currently in preclinical testing.

www.immunetune.com

 

For more information, please contact:

Sijme Zeilemaker
Chief Executive Officer
Telephone: +31 71 3322 388
E-mail: info@immunetune.com